Pluristem Therapeutics (NASDAQ:PSTI) received a $3.00 price objective from equities research analysts at Maxim Group in a research note issued on Wednesday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s price objective would suggest a potential upside of 120.59% from the company’s previous close.
Other equities analysts also recently issued reports about the stock. Zacks Investment Research raised shares of Pluristem Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $3.50 target price on shares of Pluristem Therapeutics in a research note on Thursday, November 9th. Finally, ValuEngine downgraded shares of Pluristem Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, December 20th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $4.00.
Pluristem Therapeutics (NASDAQ:PSTI) opened at $1.36 on Wednesday. Pluristem Therapeutics has a 12 month low of $1.06 and a 12 month high of $2.12. The firm has a market cap of $151.93, a PE ratio of -4.25 and a beta of 0.19.
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC raised its stake in shares of Pluristem Therapeutics by 15.0% during the third quarter. Jane Street Group LLC now owns 266,043 shares of the biotechnology company’s stock worth $402,000 after buying an additional 34,742 shares during the last quarter. Heritage Investors Management Corp bought a new stake in shares of Pluristem Therapeutics during the third quarter worth approximately $113,000. Meitav Dash Investments Ltd. bought a new stake in shares of Pluristem Therapeutics during the fourth quarter worth approximately $138,000. Psagot Investment House Ltd. raised its stake in shares of Pluristem Therapeutics by 1,705.2% during the third quarter. Psagot Investment House Ltd. now owns 129,522 shares of the biotechnology company’s stock worth $196,000 after buying an additional 122,347 shares during the last quarter. Finally, ARK Investment Management LLC raised its stake in shares of Pluristem Therapeutics by 363.5% during the fourth quarter. ARK Investment Management LLC now owns 290,922 shares of the biotechnology company’s stock worth $401,000 after buying an additional 228,149 shares during the last quarter. 4.53% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/02/22/maxim-group-analysts-give-pluristem-therapeutics-psti-a-3-00-price-target.html.
About Pluristem Therapeutics
Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.